Medicaid spending on chemotherapy drugs in Alaska rises to $207,785 in 2024

In 2024, Medicaid payments in Alaska for services in the Chemotherapy Drugs category reached $207,785, according to the U.S. Department of Health and Human Services Medicaid Provider Spending database. This represented a 761.6% jump over 2023, when $24,115 in claims were reported by providers.

Throughout this article, comparisons to the previous year reference the most recent available data.

Medicaid, a public health insurance program managed at the state level and funded with federal and state government support, provides coverage for low-income people and families, seniors, children and individuals with disabilities, making it a key component of the U.S. health care system.

Since Medicaid funding comes from taxpayers, local billing changes reflect how public health care resources are used in each community.

The Chemotherapy Drugs category refers to a group of services billed to Medicaid, categorized by care type according to standardized HCPCS and CPT code groups. For this analysis, each billing code was sorted into a single service category through consistent code groupings, preventing double counting and maintaining accuracy for longitudinal comparisons.

Some categories may comprise multiple underlying service types. In such cases, the category groups related care forms that Medicaid providers commonly bill together, including office visits, diagnostic procedures, and therapeutic treatments.

Between 2018 and 2024, Alaska Medicaid payments for Chemotherapy Drugs increased by $205,929—an 11,095.3% rise. Growth in spending was particularly pronounced during certain years, including notable gains in 2023.

By comparison, overall statewide Medicaid payments in Alaska across all claim categories grew 4.5% from 2023 to 2024.

Although many service categories saw increased Medicaid payments, Chemotherapy Drugs ranked among the top 21 categories statewide in 2024 by total payments.

Centers for Medicare & Medicaid Services data shows federal and state Medicaid spending reached approximately $871.7 billion during fiscal year 2023. This was roughly 18% of total national health expenditures and up significantly from $613.5 billion in 2019, before the COVID-19 pandemic.

This increase, about 40% over a few years, was primarily influenced by higher enrollment levels and increased usage during and in the aftermath of the pandemic.

Recent federal legislation during the Trump administration has included major initiatives aimed at reducing federal Medicaid funding and shifting program structure. The “One Big Beautiful Bill Act,” enacted in 2025, is expected to decrease federal Medicaid spending by more than $1 trillion over the next ten years, by instituting measures such as work requirements and higher cost-sharing, which could reduce funding and benefits for certain recipients. This legislation is also likely to transfer some Medicaid costs to states and slow federal funding growth, even as Medicaid continues to cover tens of millions in the United States.